The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
Age: Adults aged 40 years or older.
Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.
Currently pregnant.
Presence of any active infectious diseases.
Use of anticoagulant or antiplatelet drugs within the past 2 weeks.
Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.
Javier Toledo
Lead sponsor
Dysplasia Diagnostics Limited
Sponsor institution